Ratio Therapeutics and PharmaLogic Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358
![Ratio Therapeutics and PharmaLogic Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358](https://images.unsplash.com/photo-1543286386-713bdd548da4?auto=format&fit=crop&w=1600&q=70)
Expanded collaboration adds manufacturing capacity, strengthens redundancy, and supports later-stage development planning for Ratio's lead FAP-targeted radiotherapeutic candidate BOSTON, May 29, 2026 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing...
Expanded collaboration adds manufacturing capacity, strengthens redundancy, and supports later-stage development planning for Ratio's lead FAP-targeted radiotherapeutic candidate BOSTON, May 29, 2026 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.